OBJECTIVE: To assess influenza-related secondary complications and healthcare use and costs in patients prescribed oseltamivir for influenza. RESEARCH DESIGN AND METHODS: This study examined health insurance claims data for patients diagnosed with influenza during five influenza seasons. Patients prescribed oseltamivir were propensity matched with patients not prescribed antiviral therapy. MAIN OUTCOME MEASURES: Clinical outcomes were diagnosis with pneumonia, otitis media and hospitalizations, along with in-patient, out-patient and pharmacy use and costs. RESULTS: Each group included 45,751 patients. Patients prescribed oseltamivir had significant reductions in the risks of pneumonia (odds ratio [OR]: 0.89, 95% CI: 0.80, 1.00), otitis media (OR: 0.84, 95% CI: 0.77, 0.91) and hospitalization (OR: 0.71, 95% CI: 0.62, 0.83). The risks of pneumonia and otitis media were also lower in children and adolescents (< or = 17 years) prescribed oseltamivir (OR: 0.74, 95% CI: 0.60, 0.91 and OR: 0.77, 95% CI: 0.69, 0.85, respectively). Total healthcare costs were lower for patients prescribed oseltamivir versus no antiviral therapy (mean US$500 versus 510; p < 0.0001). Patients prescribed oseltamivir had fewer claims per patient for antibiotics (0.37 versus 0.45; p < 0.0001), fewer physician visits (1.72 versus 1.78; p < 0.0001), emergency room visits (0.11 versus 0.12; p < 0.0001), and spent fewer days in hospital (0.04 versus 0.05; p < 0.0001). CONCLUSION: The risks of influenza-related complications and hospitalization, as well as healthcare use and costs, were lower for patients prescribed oseltamivir than for those with no antiviral prescription.
OBJECTIVE: To assess influenza-related secondary complications and healthcare use and costs in patients prescribed oseltamivir for influenza. RESEARCH DESIGN AND METHODS: This study examined health insurance claims data for patients diagnosed with influenza during five influenza seasons. Patients prescribed oseltamivir were propensity matched with patients not prescribed antiviral therapy. MAIN OUTCOME MEASURES: Clinical outcomes were diagnosis with pneumonia, otitis media and hospitalizations, along with in-patient, out-patient and pharmacy use and costs. RESULTS: Each group included 45,751 patients. Patients prescribed oseltamivir had significant reductions in the risks of pneumonia (odds ratio [OR]: 0.89, 95% CI: 0.80, 1.00), otitis media (OR: 0.84, 95% CI: 0.77, 0.91) and hospitalization (OR: 0.71, 95% CI: 0.62, 0.83). The risks of pneumonia and otitis media were also lower in children and adolescents (< or = 17 years) prescribed oseltamivir (OR: 0.74, 95% CI: 0.60, 0.91 and OR: 0.77, 95% CI: 0.69, 0.85, respectively). Total healthcare costs were lower for patients prescribed oseltamivir versus no antiviral therapy (mean US$500 versus 510; p < 0.0001). Patients prescribed oseltamivir had fewer claims per patient for antibiotics (0.37 versus 0.45; p < 0.0001), fewer physician visits (1.72 versus 1.78; p < 0.0001), emergency room visits (0.11 versus 0.12; p < 0.0001), and spent fewer days in hospital (0.04 versus 0.05; p < 0.0001). CONCLUSION: The risks of influenza-related complications and hospitalization, as well as healthcare use and costs, were lower for patients prescribed oseltamivir than for those with no antiviral prescription.
Authors: Jonathan Hsu; Nancy Santesso; Reem Mustafa; Jan Brozek; Yao Long Chen; Jessica P Hopkins; Adrienne Cheung; Gayane Hovhannisyan; Liudmila Ivanova; Signe A Flottorp; Ingvil Saeterdal; Arthur D Wong; Jinhui Tian; Timothy M Uyeki; Elie A Akl; Pablo Alonso-Coello; Fiona Smaill; Holger J Schünemann Journal: Ann Intern Med Date: 2012-02-27 Impact factor: 25.391
Authors: Charles R Beck; Rachel Sokal; Nachiappan Arunachalam; Richard Puleston; Anna Cichowska; Anthony Kessel; Maria Zambon; Jonathan S Nguyen-Van-Tam Journal: Influenza Other Respir Viruses Date: 2013-01 Impact factor: 4.380
Authors: Aimee K Zaas; Minhua Chen; Jay Varkey; Timothy Veldman; Alfred O Hero; Joseph Lucas; Yongsheng Huang; Ronald Turner; Anthony Gilbert; Robert Lambkin-Williams; N Christine Øien; Bradly Nicholson; Stephen Kingsmore; Lawrence Carin; Christopher W Woods; Geoffrey S Ginsburg Journal: Cell Host Microbe Date: 2009-08-06 Impact factor: 21.023
Authors: Charisma Y Atkins; Anita Patel; Thomas H Taylor; Matthew Biggerstaff; Toby L Merlin; Stephanie M Dulin; Benjamin A Erickson; Rebekah H Borse; Robert Hunkler; Martin I Meltzer Journal: Emerg Infect Dis Date: 2011-09 Impact factor: 6.883